Targeted immunotherapy for pediatric solid tumors.

ABSTRACT: Metastatic and refractory pediatric solid tumor malignancies continue to have a poor outcome despite the > 80% cure rates appreciated in many pediatric cancers. Targeted immunotherapy is impacting treatment and survival in these aggressive tumors. We review current promising immunotherapeutic approaches in the pediatric oncology solid tumor setting.

SUBMITTER: Kopp LM 

PROVIDER: S-EPMC4839383 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature